Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × NETWORK × belantamab mafodotin × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

OTHER 11 INDUSTRY 4 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Immunoglobulin Light-chain Amyloidosis 1

Interventions

Cisplatin 105 Radiotherapy 96 Paclitaxel 73 Cyclophosphamide 72 Gemcitabine 65 Carboplatin 60 Etoposide 46 Docetaxel 46 Fluorouracil 45 Filgrastim 44 Doxorubicin 44 Vincristine 39 Leucovorin 35 Dexamethasone 32 Cytarabine 32 Capecitabine 32 Methotrexate 31 Irinotecan 31 Prednisone 30 Oxaliplatin 27 Rituximab 23 durvalumab 22 Cetuximab 22 Radiotherapy, Intensity-Modulated 21 Bevacizumab 21 Temozolomide 20 Magnetic Resonance Spectroscopy 20 Bortezomib 20 Surgical Procedures, Operative 19 Peripheral Blood Stem Cell Transplantation 19

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04617925 2025-09-05

EMN27

European Myeloma Network B.V.

Phase 2 Completed

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡